acetyl-l-carnitine neuropathic pain meta-analysis 2019 randomized Novel Drug Targets and Emerging Pharmacotherapies in Current Evidence of Acetyl-L-Carnitine use

Endpoints The primary endpoint was symptomatic remission defined according to PRO2 as the absence of bleeding, normalization of transit (Mayo stool frequency subscore=0) and no steroid

Initially, the result may be subtle, but over time, it can potentially brighten your skin complexion

Clinical Research Findings: SUSTAIN and PIONEER Trials A comprehensive safety analysis of 11,159 patients with type 2 diabetes across the SUSTAIN and PIONEER phase IIIa clinical trial programs found that gastrointestinal disorders occurred in 41.9% of patients receiving subcutaneous semaglutide and 39.1% receiving oral semaglutide, compared to 22.0% and 24.8% in comparator groups, respectively

Saiman L, Mayer-Hamblett N, Campbell P, Marshall BC

Stecher et al., 2007)